Edition:
United Kingdom

Aptevo Therapeutics Inc (APVO.OQ)

APVO.OQ on NASDAQ Stock Exchange Global Select Market

0.89USD
5:45pm BST
Change (% chg)

$0.02 (+2.19%)
Prev Close
$0.87
Open
$0.89
Day's High
$0.90
Day's Low
$0.89
Volume
72,167
Avg. Vol
133,582
52-wk High
$5.80
52-wk Low
$0.67

Latest Key Developments (Source: Significant Developments)

Aptevo Therapeutics Says Had Cash, Cash Equivalents, & Short-Term Investments As Of Dec 31, 2018 Totaling $38.1 Mln
Monday, 18 Mar 2019 

March 18 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.APTEVO THERAPEUTICS -HAD CASH, CASH EQUIVALENTS, & SHORT-TERM INVESTMENTS AS OF DEC 31, 2018 TOTALING $38.1 MILLION, INCLUDING $7.5 MILLION IN RESTRICTED CASH.  Full Article

Aptevo Announces Proposed Public Offering Of Common Stock And Warrants
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Aptevo Therapeutics Inc ::APTEVO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS.  Full Article

Aptevo Therapeutics Announces Expanded Growth Initiatives
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS ANNOUNCES EXPANDED GROWTH INITIATIVES FOR IXINITY.APTEVO THERAPEUTICS INC - PLANS TO INTRODUCE 3000 IU IXINITY ASSAY.APTEVO THERAPEUTICS INC - WILL COMMENCE PEDIATRIC STUDY SEEKING U.S. LABEL EXPANSION.APTEVO THERAPEUTICS INC - EXPLORES EX-US LICENSING AND PARTNERSHIP COLLABORATIONS TO EXPAND INTERNATIONAL IXINITY FOOTPRINT.APTEVO - PLANS TO COMMENCE PHASE 4 STUDY OF IXINITY IN ABOUT 20 PATIENTS UNDER 12 YRS AGE FOR POTENTIAL LABEL EXPANSION OF IXINITY IN PEDIATRIC SETTING.APTEVO THERAPEUTICS INC - ANTICIPATES NEW 3000 IU VIAL ASSAY FOR IXINITY WILL BE AVAILABLE IN MID-2019.APTEVO THERAPEUTICS INC - ANTICIPATES LAUNCH OF NEW 3000 IU VIAL ASSAY FOR IXINITY WILL BE AVAILABLE IN MID-2019.  Full Article

Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA.APTEVO THERAPEUTICS INC- ‍EXPECTS TO FILE 2 IND APPLICATIONS IN 2018 FOR 2 BISPECIFIC ANTIBODY CANDIDATES, APVO436 AND APVO210​.  Full Article

Aptevo Therapeutics files mixed shelf of up to $150 mln
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Aptevo Therapeutics Inc :Aptevo Therapeutics Inc files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

Aptevo Therapeutics reports third quarter 2017 financial results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aptevo Therapeutics Inc :Aptevo Therapeutics reports third quarter 2017 financial results.Q3 earnings per share $1.77.  Full Article